Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MEDI beats Street estimate

MedImmune (MEDI) reported second quarter adjusted EPS of $0.06, beating the Street's $0.03

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE